Tropical Journal of Pharmaceutical Research

Commentary | OPEN ACCESS

Approach to Publishing Adverse Event Case Reports in Biomedical Journals

Kazeem A Oshikoya

¹Pharmacology Department, Lagos State University College of Medicine, PMB 21266, Ikeja, Lagos, Nigeria; ²Academic Division of Child Health, The Medical School in Derby, Royal Derby Children's Hospital, Uttoxeter Road, Derby DE 22 3DT, United Kingdom.

For correspondence:- Email: medmodhospital@yahoo.com Tel:+447961284468

Received: 13 August 2010 Accepted: 28 November 2010 Published: 14 February 2011

Citation: Oshikoya KA. Approach to Publishing Adverse Event Case Reports in Biomedical Journals. Trop J Pharm Res 2011; 10(1):3-9 doi: 10.4314/tjpr.v10i1.2

© 2011 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Case reports describing suspected adverse events of drugs and medical products are important for post-marketing safety monitoring. Such reports could help identify potential product-associated risks and serve as signals of possible events that may require further studies. They also serve as legal documents and have been used as evidence in “toxic tort” litigation. Lack of relevant details in the reports would render them of limited value and misleading. Deficiencies in the previously published adverse event case reports in some biomedical journals from developing countries clearly illustrate a need for guidelines. A properly documented report should provide details to enable readers make differential diagnoses, ascertain the causality of the reaction to the suspected drug, and provide pharmacological and biological explanations for the reaction. Authors should also report the suspected events to the National Pharmacovigilance Centre to ensure their inclusion in adverse drug reaction databases. Reviewers and journal editors should be well familiar with adverse drug event reporting guidelines to enable them weed out junk manuscripts. It would seem reasonable to include such guidelines in the instructions for authors, should a journal continue to publish case reports of adverse drug events.

Keywords: Adverse drug events, Reporting and publishing, Biomedical journals, Developing countries